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LETTER TO THE EDITOR
Improvement in diagnostic delays 
over time in patients with hereditary 
angioedema: findings from the Icatibant 
Outcome Survey
Andrea Zanichelli1*, Markus Magerl2, Hilary J. Longhurst3,10, Werner Aberer4, Teresa Caballero5, 
Laurence Bouillet6, Anette Bygum7, Anete S. Grumach8, Jaco Botha9, Irmgard Andresen9 
and Marcus Maurer2 on behalf of the IOS Study Group
Abstract 
The objective of this analysis was to evaluate the change over time in age at first symptoms, age at diagnosis, and 
delay in diagnosis using data from the Icatibant Outcome Survey (IOS). Patients with a diagnosis of C1-INH-HAE who 
were born before the year 1990 and who were diagnosed before they reached 25 years of age were included in the 
analysis. Both age at diagnosis and delay in diagnosis of C1-INH-HAE appear to decline with later decade of birth, 
despite wide variation across the countries assessed, suggesting that improved disease awareness causes increased 
rates of earlier diagnosis over time. Our findings demonstrate that some patients are still experiencing long delays to 
diagnosis, indicating an ongoing need for improved disease awareness.
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To the Editor,
Hereditary angioedema due to C1 inhibitor deficiency 
or dysfunction (type I or type II; C1-INH-HAE) is a rare 
genetic disease characterized by repeated episodes of 
bradykinin-mediated swelling in subcutaneous or sub-
mucosal tissues [1, 2]. C1-INH-HAE is often poorly 
recognized because of its nonspecific signs and symp-
toms. As a result, misdiagnoses and delays in obtaining 
a correct diagnosis are common [3, 4]. The impact of a 
late diagnosis can be high, as initiation of appropriate 
therapy is delayed, putting patients at increased risk of 
morbidity and mortality [4, 5] and leading to unnecessary 
medical or surgical procedures [6]. Given the young age 
of patients at symptom onset, a delayed diagnosis may 
cause disruption of education or early working life, and 
significantly impacts quality of life and social involve-
ment [7, 8]. Although awareness of C1-INH-HAE has 
improved over recent decades, it is not clear if this has 
translated into earlier diagnosis. Here, we evaluated the 
change in age at first symptoms, age at diagnosis, and 
delay in diagnosis by decade of birth in patients with 
C1-INH-HAE enrolled in the Icatibant Outcome Survey 
(IOS). IOS is an ongoing, international, multicenter, pro-
spective, observational study (NCT01034969) designed 
to monitor the safety and effectiveness of icatibant, a 
bradykinin  B2 receptor antagonist [9].
As of January 2017, 11 countries (Austria, Brazil, Czech 
Republic, Denmark, France, Germany, Greece, Israel, Italy, 
Spain, and the United Kingdom) were involved in the reg-
istry. Participation is voluntary, at the discretion of the 
physician and the patient, and patients are managed under 
the direction of their physician in accordance with rou-
tine clinical practice. Patient data, including year of birth, 
age at diagnosis, and delay between symptom onset and 
diagnosis, are collected by physicians using a web-based 
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electronic case report form at the time of enrollment, and 
during subsequent routine examinations or visits to man-
age angioedema attacks. Written informed consent is 
obtained from all patients prior to enrollment in IOS. IOS 
is conducted in accordance with the Declaration of Hel-
sinki and the International Conference on Harmonization 
Good Clinical Practice Guidelines, and with approval from 
local ethics committees and/or health authorities.
This analysis included patients with C1-INH-HAE who 
were born before 1990 and diagnosed before the age of 25 
years. Patients diagnosed before the onset of symptoms, 
owing to a family history of C1-INH-HAE, were excluded. 
Data were collected from July 2009 through January 2017. 
Owing to the observational nature of the registry, all analy-
ses were considered exploratory and no adjustment for 
multiplicity was performed. Linear regression analyses 
were performed to determine the correlation between time 
to event parameters and decade of birth, with a statistical 
significance level of α = 0.05.
As of January 2017, 250 patients with C1-INH-HAE 
type I (n = 240) or type II (n = 10) enrolled in IOS met 
the inclusion criteria. Of these, 139 (55.6%) were female. 
Median age at onset of symptoms was 9.0 years (interquar-
tile range [IQR]: 4.0–16.0 years), median age at diagnosis 
was 16.7  years (IQR: 10.1–19.8  years), and median delay 
in diagnosis was 2.6 years (IQR: 0.1–9.7 years; Fig. 1a–c). 
There was considerable variation among countries, with 
median age at onset of symptoms ranging from 0.5 to 
12.0  years, median age at diagnosis ranging from 13.5 to 
22.3  years, and median delay in diagnosis ranging from 
0.13 to 17.3 years (Fig. 1a–c).
Using linear regression analysis, we found that age at 
diagnosis and delay in diagnosis both declined with later 
decade of birth (p ≤ 0.0001, Pearson correlation coefficient 
r = − 0.2659; and p = 0.0029, r = − 0.1874, respectively). 
Patients born during 1950–1960 (n = 24) were diagnosed 
at a median age of 20.2 years compared with 15.4 years for 
those born during 1980–1990 (n = 94), whereas patients 
born during 1950–1960 experienced a delay in diagnosis 
of 7.0 years compared with 1.4 years for those born during 
1980–1990. Age at symptom onset remained unchanged 
irrespective of decade of birth (Fig.  2a–c). Patients with 
a family history of C1-INH-HAE (n = 180; 72.0%) had 
a median delay in diagnosis of 2.0  years compared with 
5.6  years for those with no or unknown family history 
(p = 0.0092).
Our findings demonstrate improvements in C1-INH-
HAE diagnosis over time, with patients now more fre-
quently being diagnosed at a younger age, and with shorter 
delays between symptom onset and diagnosis. However, 
patients diagnosed prior to symptom onset were excluded 
from this analysis, precluding the evaluation of diagnosis 
rates for those with a family history of HAE. Though data 
from registries such as IOS provide a valuable source of 
real-world information, the voluntary nature of participa-
tion presents a number of limitations, including missing 
or incomplete data and potential selection bias. Almost 
two-thirds of patients included in this analysis were born 
between 1970 and 1990, suggestive of a potential bias 
towards recently diagnosed patients. Of note, some patients 
are still experiencing long delays to diagnosis, indicating an 
ongoing need for improved disease awareness.
(See figure on previous page.)
Fig. 1 a Age at symptom onset by country. b Age at diagnosis by country. c Delay in diagnosis by country. The horizontal line inside each box 
indicates the median, the lower and upper borders of each box indicate the first and third quartiles, and the lower and upper box whiskers indicate 
the minimum and maximum values
Fig. 2 a Age at symptom onset by decade of birth. b Age at diagnosis by decade of birth. c Delay in diagnosis by decade of birth. The horizontal 
line inside each box indicates the median, the lower and upper borders of each box indicate the first and third quartiles, and the lower and upper 
box whiskers indicate the minimum and maximum values
(See figure on next page.)
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